Skip to main content
Clinical Trials/NCT06347445
NCT06347445
Completed
Not Applicable

Turkish Nationwide SurvEy of Glycemic and Other Metabolic Parameters of Patients With Diabetes Mellitus-2 (TEMD-2 Study)

Gulhane School of Medicine1 site in 1 country5,707 target enrollmentOctober 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus
Sponsor
Gulhane School of Medicine
Enrollment
5707
Locations
1
Primary Endpoint
Glycemia control status of Turkish adult patients with diabetes mellitus
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This study evaluates the metabolic control status, cardiovascular risk and frequency of comorbidities in diabetic patients followed in tertiary treatment centers in Turkey.

Detailed Description

Diabetes mellitus is one of the most common chronic diseases worldwide.The prevalence of diabetes is increased significantly in Türkiye, from 7.2 % in 2002 to 13.7% in 2012. This increasing prevalence leads to serious public health problems and a significant economic burden. Many important diseases such as hypertension and dyslipidemia accompany the picture in diabetic patients. The optimal treatment of diabetes and prevention of diabetic complications, especially the cardiovascular outcomes, is utmost important. Although achieving glycemic targets in patients with diabetes is of great importance, blood glucose is not the only predictor of cardiovascular outcome in diabetes. Optimization of other metabolic parameters such as lipids, arterial blood pressure (ABP), and body weight as well as a healthy lifestyle are utmost important. Common problems in diabetic patients, such as sleep disorders and sexual dysfunction, affect glycemia regulation in these patients.There is little data on the frequency of these diseases in diabetic patients in Türkiye. In the TEMD-1 study conducted in 2017, the rates of diabetic patients achieving metabolic goals and the factors affecting these rates were revealed in Turkish patients with diabetes. The findings obtained in the current study will be compared with the findings in 2017, and in addition, the frequency of comorbidities such as sleep disorder, sexual dysfunction, and depression will be tried to be revealed.

Registry
clinicaltrials.gov
Start Date
October 1, 2022
End Date
January 30, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Gulhane School of Medicine
Responsible Party
Principal Investigator
Principal Investigator

cem haymana

Associate Proffesor

Gulhane School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Patients with type 1 or type 2 diabetes
  • Upper than 18 years old
  • To be under follow-up in the same center for at least one year.

Exclusion Criteria

  • Pregnant or lactation period
  • Younger than 18 years old
  • History of psychiatric disorders interfering cognition or compliance

Outcomes

Primary Outcomes

Glycemia control status of Turkish adult patients with diabetes mellitus

Time Frame: 7 days

Glycemia control will be defined as good control if the mean HbA1c level of patients \< 7% or poor control if the mean HbA1c level of patient between 7% and 9% and very poor control if the mean HbA1c level of patient \> 9%

Blood pressure control status of Turkish adult patients with diabetes mellitus

Time Frame: 7 days

Home blood pressure \<135/85 mmHg or office blood pressure \<140/90 mmHg will be defined as under control.

Weight control status of Turkish adult patients with diabetes mellitus.

Time Frame: 7 days

Body mass index \< 30 kg/m2 will be defined as under control. Weight and height will be combined to report body mass index in kg/m2.

Lipid control status of Turkish adult patients with diabetes mellitus.

Time Frame: 7 days

Triglyceride \< 150 mg/dl, LDL-C \<55 mg/dl, \<70 mg/dl and \< 100 mg/dl according to the cardiovascular risk status, HDL-C \> 40 mg/dl for men, and HDL-C \> 50 mg/dl for women will be defined as under control.

Study Sites (1)

Loading locations...

Similar Trials